158 related articles for article (PubMed ID: 21798065)
21. Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact.
Hildenbrand R; Schaaf A; Dorn-Beineke A; Allgayer H; Sütterlin M; Marx A; Stroebel P
Histol Histopathol; 2009 Jul; 24(7):869-77. PubMed ID: 19475533
[TBL] [Abstract][Full Text] [Related]
22. CD44 enhances invasion of basal-like breast cancer cells by upregulating serine protease and collagen-degrading enzymatic expression and activity.
Montgomery N; Hill A; McFarlane S; Neisen J; O'Grady A; Conlon S; Jirstrom K; Kay EW; Waugh DJ
Breast Cancer Res; 2012 May; 14(3):R84. PubMed ID: 22621373
[TBL] [Abstract][Full Text] [Related]
23. Nimbolide inhibits invasion and migration, and down-regulates uPAR chemokine gene expression, in two breast cancer cell lines.
Elumalai P; Brindha Mercy A; Arunkamar R; Sharmila G; Bhat FA; Balakrishnan S; Raja Singh P; Arunakaran J
Cell Prolif; 2014 Dec; 47(6):540-52. PubMed ID: 25377085
[TBL] [Abstract][Full Text] [Related]
24. Elevated urokinase-specific surface receptor expression is maintained through its interaction with urokinase plasminogen activator.
Mahanivong C; Yu J; Huang S
Mol Carcinog; 2007 Mar; 46(3):165-75. PubMed ID: 17186542
[TBL] [Abstract][Full Text] [Related]
25. Impairment of breast cancer cell invasion by COX-2-specific inhibitor NS398: roles of CXCR4 and of uPA system.
Silva HC; Alves V; Nogueira LA; Rosa MS; Carvalho L; Regateiro F
Med Oncol; 2012 Sep; 29(3):1468-76. PubMed ID: 21638077
[TBL] [Abstract][Full Text] [Related]
26. Small-molecule inhibition of the uPAR·uPA interaction: synthesis, biochemical, cellular, in vivo pharmacokinetics and efficacy studies in breast cancer metastasis.
Mani T; Wang F; Knabe WE; Sinn AL; Khanna M; Jo I; Sandusky GE; Sledge GW; Jones DR; Khanna R; Pollok KE; Meroueh SO
Bioorg Med Chem; 2013 Apr; 21(7):2145-55. PubMed ID: 23411397
[TBL] [Abstract][Full Text] [Related]
27. TGF-β2 promotes RPE cell invasion into a collagen gel by mediating urokinase-type plasminogen activator (uPA) expression.
Sugioka K; Kodama A; Okada K; Iwata M; Yoshida K; Kusaka S; Matsumoto C; Kaji H; Shimomura Y
Exp Eye Res; 2013 Oct; 115():13-21. PubMed ID: 23810810
[TBL] [Abstract][Full Text] [Related]
28. Microglia and the urokinase plasminogen activator receptor/uPA system in innate brain inflammation.
Cunningham O; Campion S; Perry VH; Murray C; Sidenius N; Docagne F; Cunningham C
Glia; 2009 Dec; 57(16):1802-14. PubMed ID: 19459212
[TBL] [Abstract][Full Text] [Related]
29. Prevention of breast cancer growth, invasion, and metastasis by antiestrogen tamoxifen alone or in combination with urokinase inhibitor B-428.
Xing RH; Mazar A; Henkin J; Rabbani SA
Cancer Res; 1997 Aug; 57(16):3585-93. PubMed ID: 9270032
[TBL] [Abstract][Full Text] [Related]
30. Inhibitory effect of emodin on migration, invasion and metastasis of human breast cancer MDA-MB-231 cells in vitro and in vivo.
Sun Y; Wang X; Zhou Q; Lu Y; Zhang H; Chen Q; Zhao M; Su S
Oncol Rep; 2015 Jan; 33(1):338-46. PubMed ID: 25370743
[TBL] [Abstract][Full Text] [Related]
31. Angiogenin interacts with the plasminogen activation system at the cell surface of breast cancer cells to regulate plasmin formation and cell migration.
Dutta S; Bandyopadhyay C; Bottero V; Veettil MV; Wilson L; Pins MR; Johnson KE; Warshall C; Chandran B
Mol Oncol; 2014 May; 8(3):483-507. PubMed ID: 24457100
[TBL] [Abstract][Full Text] [Related]
32. Expression of urokinase-type plasminogen activator (uPA), its receptor (uPAR), and inhibitor (PAI-1) in human breast carcinomas and their clinical relevance.
Andres SA; Edwards AB; Wittliff JL
J Clin Lab Anal; 2012 Feb; 26(2):93-103. PubMed ID: 22467324
[TBL] [Abstract][Full Text] [Related]
33. Suppression of FOXQ1 in benzyl isothiocyanate-mediated inhibition of epithelial-mesenchymal transition in human breast cancer cells.
Sehrawat A; Kim SH; Vogt A; Singh SV
Carcinogenesis; 2013 Apr; 34(4):864-73. PubMed ID: 23276794
[TBL] [Abstract][Full Text] [Related]
34. Role of urokinase plasminogen activator receptor in thrombospondin 1-mediated tumor cell invasion.
Albo D; Berger DH; Rothman VL; Tuszynski GP
J Surg Res; 1999 Apr; 82(2):331-8. PubMed ID: 10090848
[TBL] [Abstract][Full Text] [Related]
35. Targeting of urokinase plasminogen activator receptor in human pancreatic carcinoma cells inhibits c-Met- and insulin-like growth factor-I receptor-mediated migration and invasion and orthotopic tumor growth in mice.
Bauer TW; Liu W; Fan F; Camp ER; Yang A; Somcio RJ; Bucana CD; Callahan J; Parry GC; Evans DB; Boyd DD; Mazar AP; Ellis LM
Cancer Res; 2005 Sep; 65(17):7775-81. PubMed ID: 16140945
[TBL] [Abstract][Full Text] [Related]
36. Selective abrogation of the uPA-uPAR interaction in vivo reveals a novel role in suppression of fibrin-associated inflammation.
Connolly BM; Choi EY; Gårdsvoll H; Bey AL; Currie BM; Chavakis T; Liu S; Molinolo A; Ploug M; Leppla SH; Bugge TH
Blood; 2010 Sep; 116(9):1593-603. PubMed ID: 20466854
[TBL] [Abstract][Full Text] [Related]
37. Maspin regulates hypoxia-mediated stimulation of uPA/uPAR complex in invasive breast cancer cells.
Amir S; Margaryan NV; Odero-Marah V; Khalkhali-Ellis Z; Hendrix MJ
Cancer Biol Ther; 2005 Apr; 4(4):400-6. PubMed ID: 15846059
[TBL] [Abstract][Full Text] [Related]
38. [Correlation of p38 mitogen-activated protein kinase signal transduction pathway to uPA expression in breast cancer].
Han YC; Zeng XX; Wang R; Zhao Y; Li BL; Song M
Ai Zheng; 2007 Jan; 26(1):48-53. PubMed ID: 17222367
[TBL] [Abstract][Full Text] [Related]
39. The urokinase plasminogen activator system in breast cancer invasion and metastasis.
Tang L; Han X
Biomed Pharmacother; 2013 Mar; 67(2):179-82. PubMed ID: 23201006
[TBL] [Abstract][Full Text] [Related]
40. The effects of cyclooxygenase2-prostaglandinE2 pathway on Helicobacter pylori-induced urokinase-type plasminogen activator system in the gastric cancer cells.
Iwamoto J; Mizokami Y; Takahashi K; Matsuoka T; Matsuzaki Y
Helicobacter; 2008 Jun; 13(3):174-82. PubMed ID: 18466392
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
